Sexually Transmitted Diseases

Andrea L. Cox, MD, PhD, discusses the implications of discovering that an experimental vaccine was not effective at preventing chronic hepatitis C virus.

A new study provides evidence that more needs to be done to meet the needs of children in rural Zimbabwe who are exposed to HIV.

Regardless of HIV status, frailty was a strong predictor for mortality and comorbidity for middle-aged adults.

Through the platform providers, consumers, and procurers will have access to full prescribing inserts and FDA-reviewed product labeling which will provide additional important information to patients and providers.

Daniel Chastain, PharmD, BCIDP, discusses how antiretroviral stewardship might practically be implemented in the context that antimicrobial stewardship as a whole is often underdeveloped.

Max Brito, MD, MPH, explains the value of bringing safe, confidential, and non-stigmatizing HIV treatment to the community at IDWeek2019.

Standalone HIV testing centers in San Diego County, California, have been largely effective at reaching people at high risk of infection, according to a new study that also identified areas where targeted testing efforts may be beneficial.

Babies born with HIV benefit from beginning ART with days—not weeks—of birth.

A study has revealed the ways Mycoplasma genitalium competes with host organism cells for essential metal nutrients.

Andrea L. Cox, MD, PhD, compares the rates of hepatitis C and hepatitis B diagnoses since the start of the opioid epidemic.

Public Health England reported the promising news that new HIV transmission in the UK continued to decline in 2018.

Using a trial of antibiotics may be useful for predicting tuberculosis in ambulatory patients with HIV, particularly in settings with limited access to resources, a new study suggests.

Although antiretroviral therapy restores a patient with HIV’s immune system, lingering damage from HIV can render past vaccinations obsolete, a new study finds.

A new study conducted by CDC investigators found that commercially insured patients persisted on PrEP for median time of 13.7 months, compared to 6.8 months among Medicaid patients.

The prevalence of NTDs in pregnancies among women with diagnosed HIV infection was 7.0 per 10,000 live births, which was similar to that among the general population.

New legislation, cost assistance program will likely reduce transmission.

Over the past decade and a half, more Americans have begun to receive STD-related diagnoses and care in a primary care setting. New recommendations from the CDC aim to help ensure quality care amid the shift.

Roughly half of all American expectant mothers living with HIV are receiving treatments that don’t meet federal guidelines. A new study examines prescribing choices for this population.

Viral suppression at 2 years nearly doubled for people with HIV in a medical care coordination program implemented by the Los Angeles County Division of HIV and STD Programs, a new study found.

Contagion® counts down the top HIV news stories of 2019, including FDA approvals, breakthrough discoveries, recommendations from the frontlines, and a big-picture look at just how close we are to ending the epidemic.

A new study out of Africa demonstrates that maternal-child clinics may act as a one-stop shop for both pregnancy and postpartum concerns and HIV protection.

Vaccinating adults ages 27-45 years against human papillomavirus (HPV) was projected to have low public health benefits and high costs, according to a new report.

The FDA has issused a complete response letter to ViiV Healthcare for cabotegravir/rilpivirine.

Results suggest that PrEP provision is concentrated among those at high risk for HIV and STIs, but that more must be done to prevent STIs among those who persistently use PrEP.

Recommendations to offer antiretroviral therapy on the same day as home-based HIV testing were reinforced by a 2-year follow-up study that examined involvement in care and viral suppression.

Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.

An analysis of participants in a trial measuring the efficacy of PrEP found that sex-driven dose timing—as opposed to daily dosing—was effective in preventing HIV, even in men who had sex less often.

In April, the US Food and Drug Administration (FDA) approved dolutegravir plus lamivudine as a complete 2-drug regimen for treatment naïve adults with HIV-1.

Investigators have documented growing acceptability among sexual minority men that U=U, but with widespread overestimation of transmission risk.

Fifteen years after the launch of a program to help bring HIV treatment to low-income countries, an FDA analysis shows the program is working, but there is room for improvement.